Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Regeneron

- PMLiVE

Regeneron’s bispecific for lymphoma works in CAR-T failures

Regeneron has reported positive results with its REGN1979 drug in patients with non-Hodgkin’s lymphoma, including the evidence it can work in patients who have previously tried CAR-T therapies.The new data...

- PMLiVE

Hudson named Brandicourt’s successor as Sanofi’s CEO

Sanofi shaking off patent expiries

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

AstraZeneca AZ

Oncology drives AstraZeneca, Genzyme boosts Sanofi

Specialist drugs are growth engines in Q1

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

- PMLiVE

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

Havas Lynx Group scoops nine Golds at PM Society Awards

Sanofi Genzyme and Regeneron topped the pharma company charts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links